Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><ul type="disc"><li style="margin-top:6pt; margin-bottom:6pt;"><strong><em>Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer Initiated</em></strong></li><li style="margin-top:6pt; margin-bottom:6pt;"><strong><em>IND and Phase 1a Study for NXP900 Pending</em></strong></li><li style="margin-top:6pt; margin-bottom:6pt;"><strong><em>In-Vivo...